Home

Download

Statistics

Landscape

Help

Contact

	1. Gene summary of enriched editing regions
	2. Tumor-specific enriched editing regions
	Comparison of enriched editing regions between tumor and normal.
	Correlation of enriched editing regions with tumor stages.
	Associations of enriched editing regions with cancer survival.
	3. Enriched editing regions and immune related genes
	4. Enriched editing regions and immune related splicing
	5. Enriched editing regions and immune infiltration
	6. Enriched editing regions and immune gene sets
	Correlation of enriched editing regions with epithelial-mesenchymal transition.
	Correlations of enriched editing regions with hypoxic.
	Associations of enriched editing regions with hallmark gene sets from MSigDB.
	7. Enriched editing regions and drugs
	Correlations between enriched editing regions and drug sensitivity.
	Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: RSL1D1 (ImmuneEditome ID:26156)

1. Gene summary of enriched editing regions for RSL1D1

Gene summary

Gene information	Gene symbol	RSL1D1
	Gene ID	26156
	GeneSynonyms	CSIG\|L12\|PBK1\|UTP30
	GeneCytomap	16p13.13
	GeneType	protein-coding
	GeneDescription	ribosomal L1 domain-containing protein 1\|CATX-11\|cellular senescence-inhibited gene protein
	GeneModificationdate	20230518
	UniprotID	O76021;J3QSV6;I3L3C4;I3L4T8;I3L3U9;I3L234;J3KPU7;I3L2F2;I3L1Y4
	PubMed ID

UCSC image.

Locations of each EERs.

EER	ENST	ENSG	GeneName	Region	Repeat	dsRNA structure
chr16:11834820-11835639:-	ENST00000571133.4	ENSG00000171490.11	RSL1D1	UTR3	AluJr,AluJb,AluSx1	chr16:11834820-11835639:-.alignment
chr16:11845221-11845390:-	ENST00000574823.4	ENSG00000171490.11	RSL1D1	ncRNA_intronic	AluJr	chr16:11845221-11845390:-.alignment

Top

2. Tumor-specific enriched editing regions for RSL1D1

Comparison of enriched editing regions between tumor and normal.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events	cancer	Type	P	Boxplot
chr16:11834820-11835639:-	COAD	EER	1.8774e-03
ENSG00000171490.11,RSL1D1	COAD	EAG	2.4288e-03
chr16:11834820-11835639:-	HNSC	EER	1.2876e-10
ENSG00000171490.11,RSL1D1	HNSC	EAG	1.6540e-10
chr16:11834820-11835639:-	KICH	EER	1.2440e-03
ENSG00000171490.11,RSL1D1	KICH	EAG	7.5759e-04
chr16:11834820-11835639:-	KIRP	EER	2.3120e-02
ENSG00000171490.11,RSL1D1	KIRP	EAG	2.2389e-02
chr16:11834820-11835639:-	LIHC	EER	2.7469e-03
ENSG00000171490.11,RSL1D1	LIHC	EAG	3.0560e-03
chr16:11834820-11835639:-	LUAD	EER	2.4376e-03
ENSG00000171490.11,RSL1D1	LUAD	EAG	3.6511e-03
chr16:11834820-11835639:-	LUSC	EER	3.0206e-08
ENSG00000171490.11,RSL1D1	LUSC	EAG	3.3132e-08
chr16:11834820-11835639:-	PRAD	EER	3.2865e-02
ENSG00000171490.11,RSL1D1	PRAD	EAG	2.1640e-02
chr16:11834820-11835639:-	THCA	EER	4.0109e-02
chr16:11834820-11835639:-	UCEC	EER	1.7443e-05
ENSG00000171490.11,RSL1D1	UCEC	EAG	1.6317e-05

Top

Correlation of enriched editing regions with tumor stages.

* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.

* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Type	StageType	AnovaP	P	R	Boxplot
ENSG00000171490.11,RSL1D1	BLCA	Path	EAG	2.6577e-02	1.0625e-02	0.1332
chr16:11834820-11835639:-	BLCA	Path	EER	2.5591e-02	9.8842e-03	0.1345
ENSG00000171490.11,RSL1D1	KIRC	Path	EAG	1.8020e-03	1.3726e-03	0.1400
chr16:11834820-11835639:-	KIRC	Path	EER	6.8291e-03	1.5519e-03	0.1386

Top

Associations of enriched editing regions with cancer survival.

* Pkm<0.05 and Pcox<0.05.

* EER: enriched editing region, EAG: EER-associated genes.

ID_events

cancer

TypeID

Pkm

Pcox_continuous

HR_continuous

KMPlot

Top

3. Enriched editing regions and immune related genes for RSL1D1

Enriched editing regions and immune related genes.

* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

Gene

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

chr16:11834820-11835639:-

KIRC

EER

ENSG00000197180,CH17-340M24.3

0.3045

5.6621e-07

4.0402e-17

0.4149

EIF4A3;ELAVL1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_UV_RESPONSE_DN

chr16:11834820-11835639:-

KIRC

EER

ENSG00000135441,BLOC1S1

0.2849

3.0351e-06

1.1120e-16

0.4096

CSTF2T;EIF4A3;ELAVL1;HNRNPA1;RBFOX2;RBM10

BLOC1S1

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_UV_RESPONSE_DN

chr16:11834820-11835639:-

KIRC

EER

ENSG00000166136,NDUFB8

0.2792

6.9795e-06

9.1318e-17

0.4106

CSTF2T;EIF4A3;ELAVL1;HNRNPA1;RBFOX2;RBM10

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

chr16:11834820-11835639:-

KIRP

EER

ENSG00000239569,KMT2E-AS1

0.2396

1.4187e-03

9.2149e-12

0.4015

CSTF2T;EIF4A3;ELAVL1;HNRNPA1;RBFOX2;RBM10

Macrophages_M1

GSVA_HALLMARK_ANDROGEN_RESPONSE

chr16:11834820-11835639:-

KIRP

EER

ENSG00000253764,RP11-439C15.4

0.2203

3.8570e-03

4.5116e-12

0.4069

RBFOX2

NK_cells_activated

GSVA_HALLMARK_PANCREAS_BETA_CELLS

chr16:11834820-11835639:-

DLBC

EER

ENSG00000036672,USP2

0.6269

5.8515e-03

1.5430e-04

0.5347

CSTF2T;EIF4A3;ELAVL1;HNRNPA1;RBFOX2

USP2

NK_cells_activated

chr16:11834820-11835639:-

DLBC

EER

ENSG00000125703,ATG4C

-0.6410

7.2089e-03

8.6976e-06

-0.6099

CSTF2T;EIF4A3;ELAVL1;HNRNPA1;RBFOX2;RBM10

B_cells_naive

GSVA_HALLMARK_MYOGENESIS

chr16:11834820-11835639:-

DLBC

EER

ENSG00000023041,ZDHHC6

-0.5780

2.0557e-02

7.4220e-06

-0.6135

CSTF2T;EIF4A3;ELAVL1;HNRNPA1;RBFOX2;RBM10

NK_cells_activated

GSVA_HALLMARK_MITOTIC_SPINDLE

chr16:11834820-11835639:-

DLBC

EER

ENSG00000136146,MED4

-0.5910

2.3513e-02

7.3638e-05

-0.5559

CSTF2T;EIF4A3;ELAVL1;HNRNPA1;RBFOX2;RBM10

NK_cells_resting

GSVA_HALLMARK_KRAS_SIGNALING_DN

chr16:11834820-11835639:-

DLBC

EER

ENSG00000138698,RAP1GDS1

-0.5295

3.3069e-02

4.4034e-04

-0.5021

CSTF2T;EIF4A3;ELAVL1;HNRNPA1;RBFOX2;RBM10

NK_cells_resting

GSVA_HALLMARK_MITOTIC_SPINDLE

More results

Top

4. Enriched editing regions and immune related splicing for RSL1D1

Enriched editing regions and immune related splicing.

* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).

* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events

cancer

Type

SplicingType

SplicingGene

SplicingChr

SplicingPosition

beta

FDR

PearsonP

PearsonR

CorrelationPlot

RBP

RBPtargets

ImmuneGene

ImmuneFraction

HallMark

ENSG00000171490.11,RSL1D1

KIRC

EAG

MEX

ENSG00000130159.9

chr19

11507990:11508048:11513055:11513150:11513202:11513279:11513803:11513858

0.2683

5.3203e-05

1.0200e-17

0.4216

ADAR;AIFM1;AUH;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;KHDRBS1;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;SAFB2;SF3A3;SF3B4;SLTM;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

ECSIT

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000171490.11,RSL1D1

KIRC

EAG

ENSG00000136100.8

chr13

52416016:52416093:52413153:52413226:52413153:52415923

0.1992

7.7466e-03

1.0281e-16

0.4105

ACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LIN28;LIN28A;LIN28B;LSM11;MBNL2;MOV10;MSI1;MSI2;NCBP3;NONO;NOP56;NOP58;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM47;RC3H1;RNF219;SAFB2;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

Eosinophils

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000171490.11,RSL1D1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399917:154400557:154400626:154400701:154400917

-0.3532

2.0926e-09

1.2603e-16

-0.4084

ACIN1;AIFM1;ALYREF;AUH;BCCIP;BUD13;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G1;EIF4G2;ELAVL1;EWSR1;FAM120A;FBL;FKBP4;FMR1;FTO;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM5;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARBP2;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;YWHAG;ZC3H7B;ZNF184

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000171490.11,RSL1D1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399917:154400563:154400626:154400701:154400917

-0.3532

2.0926e-09

1.2603e-16

-0.4084

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000171490.11,RSL1D1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399925:154400474:154400626:154400701:154400917

-0.3532

2.0926e-09

1.2603e-16

-0.4084

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000171490.11,RSL1D1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399925:154400557:154400626:154400701:154400917

-0.3532

2.0926e-09

1.2603e-16

-0.4084

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000171490.11,RSL1D1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399925:154400563:154400626:154400701:154400917

-0.3532

2.0926e-09

1.2603e-16

-0.4084

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000171490.11,RSL1D1

KIRC

EAG

ENSG00000144445.11

chr2

210021422:210023179:210024032:210024201

0.2057

8.2178e-03

3.4863e-21

0.4616

ACIN1;ADAR;AUH;BCCIP;BUD13;CNBP;CSTF2T;DDX42;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHSRP;LARP7;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;PCBP2;PRPF8;PTBP1;QKI;RBFOX2;RBM10;RBM27;RBM47;RBM5;RC3H1;SAFB2;SF3A3;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TRA2A;U2AF1;U2AF2;UPF1;VIM;XRN2;YTHDC1;YTHDF1;ZC3H7B;ZNF184

Eosinophils

GSVA_HALLMARK_HEME_METABOLISM

ENSG00000171490.11,RSL1D1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399945:154400474:154400626:154400701:154400811

-0.3532

2.0926e-09

1.2601e-16

-0.4084

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

ENSG00000171490.11,RSL1D1

KIRC

EAG

MEX

ENSG00000147403.12

chrX

154399486:154399594:154399802:154399945:154400557:154400626:154400701:154400811

-0.3532

2.0926e-09

1.2601e-16

-0.4084

T_cells_regulatory_(Tregs)

GSVA_HALLMARK_MITOTIC_SPINDLE

More results

Top

5. Enriched editing regions and immune infiltration for RSL1D1

Associations of enriched editing regions with immune infiltration.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	TypeID	ImmuneCell	P	R	CorrelationPlot
chr16:11834820-11835639:-	BLCA	EER	Dendritic_cells_resting	2.4699e-04	-0.1905
ENSG00000171490.11,RSL1D1	BLCA	EAG	Dendritic_cells_resting	2.5979e-04	-0.1898
chr16:11834820-11835639:-	BRCA	EER	NK_cells_activated	3.7433e-03	0.0884
ENSG00000171490.11,RSL1D1	BRCA	EAG	NK_cells_activated	8.5159e-04	0.1016
chr16:11834820-11835639:-	CESC	EER	Dendritic_cells_activated	8.0271e-04	0.1988
ENSG00000171490.11,RSL1D1	CESC	EAG	Dendritic_cells_activated	7.9018e-04	0.1991
chr16:11834820-11835639:-	COAD	EER	T_cells_CD8	1.1121e-02	0.1575
ENSG00000171490.11,RSL1D1	COAD	EAG	B_cells_naive	2.3581e-02	-0.1398
chr16:11834820-11835639:-	DLBC	EER	NK_cells_activated	9.5124e-03	0.3825
ENSG00000171490.11,RSL1D1	DLBC	EAG	NK_cells_activated	9.5124e-03	0.3825
chr16:11834820-11835639:-	ESCA	EER	NK_cells_resting	7.7275e-03	0.2125
ENSG00000171490.11,RSL1D1	ESCA	EAG	Monocytes	1.7021e-02	-0.1902
chr16:11834820-11835639:-	GBM	EER	Macrophages_M0	1.9248e-04	-0.2847
ENSG00000171490.11,RSL1D1	GBM	EAG	Macrophages_M0	2.3952e-04	-0.2806
chr16:11834820-11835639:-	HNSC	EER	B_cells_naive	1.3483e-03	-0.1473
ENSG00000171490.11,RSL1D1	HNSC	EAG	B_cells_naive	1.2749e-03	-0.1480
chr16:11834820-11835639:-	KIRC	EER	T_cells_regulatory_(Tregs)	2.0746e-04	0.1900
ENSG00000171490.11,RSL1D1	KIRC	EAG	Macrophages_M1	8.4059e-05	-0.2009
chr16:11834820-11835639:-	KIRP	EER	Neutrophils	1.7126e-02	0.1458
ENSG00000171490.11,RSL1D1	KIRP	EAG	Macrophages_M0	1.6803e-02	-0.1462
ENSG00000171490.11,RSL1D1	LAML	EAG	Macrophages_M0	3.5240e-02	-0.2152
chr16:11834820-11835639:-	LGG	EER	T_cells_CD4_naive	1.3818e-03	-0.1389
ENSG00000171490.11,RSL1D1	LGG	EAG	T_cells_CD4_naive	1.9841e-03	-0.1343
chr16:11834820-11835639:-	LIHC	EER	Mast_cells_activated	9.0956e-03	0.1417
ENSG00000171490.11,RSL1D1	LIHC	EAG	Mast_cells_activated	8.8634e-03	0.1422
chr16:11834820-11835639:-	LUSC	EER	Mast_cells_resting	1.4477e-02	-0.1122
ENSG00000171490.11,RSL1D1	LUSC	EAG	Mast_cells_resting	1.6381e-02	-0.1102
chr16:11834820-11835639:-	MESO	EER	Mast_cells_resting	4.0969e-03	-0.3157
ENSG00000171490.11,RSL1D1	MESO	EAG	Mast_cells_resting	4.3457e-03	-0.3137
chr16:11834820-11835639:-	OV	EER	B_cells_naive	2.0961e-02	-0.1374
ENSG00000171490.11,RSL1D1	OV	EAG	B_cells_naive	1.7009e-02	-0.1418
chr16:11834820-11835639:-	PAAD	EER	Macrophages_M0	1.6369e-04	0.2844
ENSG00000171490.11,RSL1D1	PAAD	EAG	Macrophages_M0	1.7900e-04	0.2827
chr16:11834820-11835639:-	PCPG	EER	T_cells_regulatory_(Tregs)	1.8231e-02	0.1749
ENSG00000171490.11,RSL1D1	PCPG	EAG	T_cells_regulatory_(Tregs)	2.4254e-02	0.1670
chr16:11834820-11835639:-	PRAD	EER	Neutrophils	2.8909e-03	-0.1334
ENSG00000171490.11,RSL1D1	PRAD	EAG	Dendritic_cells_activated	5.2874e-05	0.1801
chr16:11834820-11835639:-	READ	EER	B_cells_naive	2.7135e-02	0.2279
ENSG00000171490.11,RSL1D1	READ	EAG	B_cells_naive	2.7711e-02	0.2271
chr16:11834820-11835639:-	SKCM	EER	Plasma_cells	1.1226e-04	0.1827
ENSG00000171490.11,RSL1D1	SKCM	EAG	Plasma_cells	7.7667e-05	0.1868
chr16:11834820-11835639:-	STAD	EER	T_cells_CD4_memory_resting	8.1352e-03	-0.1468
ENSG00000171490.11,RSL1D1	STAD	EAG	T_cells_CD4_memory_resting	1.0483e-02	-0.1416
ENSG00000171490.11,RSL1D1	TGCT	EAG	T_cells_CD4_memory_activated	6.2570e-04	0.3042
chr16:11834820-11835639:-	THCA	EER	T_cells_regulatory_(Tregs)	8.0679e-07	0.2181
ENSG00000171490.11,RSL1D1	THCA	EAG	T_cells_regulatory_(Tregs)	6.9408e-07	0.2194
chr16:11834820-11835639:-	THYM	EER	B_cells_memory	6.3097e-03	0.2566
ENSG00000171490.11,RSL1D1	THYM	EAG	B_cells_memory	5.9314e-03	0.2585
chr16:11834820-11835639:-	UCEC	EER	Dendritic_cells_resting	2.6134e-02	-0.1748
ENSG00000171490.11,RSL1D1	UCEC	EAG	Dendritic_cells_resting	2.8228e-02	-0.1724
ENSG00000171490.11,RSL1D1	UCS	EAG	Macrophages_M2	5.2042e-03	0.3717
chr16:11834820-11835639:-	UVM	EER	T_cells_follicular_helper	2.8258e-02	-0.2517
ENSG00000171490.11,RSL1D1	UVM	EAG	T_cells_follicular_helper	2.8755e-02	-0.2510

Top

6. Enriched editing regions and immune gene sets for RSL1D1

Correlation of enriched editing regions with epithelial-mesenchymal transition.

* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).

* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly edited between Epi and Mes group.

ID_events	cancer	Type	E2M_P	Boxplot	CorP	CorR	CorrelationPlot
chr16:11834820-11835639:-	KIRP	EER	1.2160e-02		1.1793e-02	-0.1539
ENSG00000171490.11,RSL1D1	KIRP	EAG	1.1877e-02		1.0797e-02	-0.1558

Top

Correlations of enriched editing regions with hypoxic.

* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.

* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.

ID_events	cancer	Type	Buffa_P	Buffa_R	Ragnum_P	Ragnum_R	Winter_P	Winter_R	HALLMARK_P	HALLMARK_R	CorrelationPlot
chr16:11834820-11835639:-	KIRC	EER	1.8457e-02	-0.1213	4.5380e-02	-0.1031	3.9539e-03	-0.1481	3.0043e-02	-0.1118
ENSG00000171490.11,RSL1D1	KIRC	EAG	3.3735e-03	-0.1504	1.2735e-02	-0.1280	1.7609e-03	-0.1604	6.0108e-03	-0.1411

Top

Associations of enriched editing regions with hallmark gene sets from MSigDB.

* P<0.05 and Informative number >=20.

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	HallmarkType	Type	P	R	CorrelationPlot
chr16:11834820-11835639:-	ACC	GSVA_HALLMARK_COAGULATION	EER	4.0841e-02	-0.2384
ENSG00000171490.11,RSL1D1	ACC	GSVA_HALLMARK_IL6_JAK_STAT3_SIGNALING	EAG	4.1264e-02	-0.2379
ENSG00000171490.11,RSL1D1	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EAG	9.6761e-06	0.2290
chr16:11834820-11835639:-	BLCA	GSVA_HALLMARK_INTERFERON_GAMMA_RESPONSE	EER	8.0794e-06	0.2309
ENSG00000171490.11,RSL1D1	BRCA	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	3.3965e-04	-0.1091
chr16:11834820-11835639:-	BRCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.6750e-05	0.1309
chr16:11834820-11835639:-	CESC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.4476e-04	0.2248
ENSG00000171490.11,RSL1D1	CESC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.6491e-04	0.2229
chr16:11834820-11835639:-	CHOL	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EER	3.3616e-03	0.4821
ENSG00000171490.11,RSL1D1	CHOL	GSVA_HALLMARK_UNFOLDED_PROTEIN_RESPONSE	EAG	3.0596e-03	0.4863
chr16:11834820-11835639:-	COAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EER	8.8835e-03	-0.1623
ENSG00000171490.11,RSL1D1	COAD	GSVA_HALLMARK_BILE_ACID_METABOLISM	EAG	6.5135e-03	-0.1677
chr16:11834820-11835639:-	DLBC	GSVA_HALLMARK_MYOGENESIS	EER	5.8398e-03	0.4046
ENSG00000171490.11,RSL1D1	DLBC	GSVA_HALLMARK_MYOGENESIS	EAG	5.8398e-03	0.4046
chr16:11834820-11835639:-	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	7.0289e-03	0.2150
ENSG00000171490.11,RSL1D1	ESCA	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	7.9035e-03	0.2113
ENSG00000171490.11,RSL1D1	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.1046e-05	0.3329
chr16:11834820-11835639:-	GBM	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	7.3357e-06	0.3392
chr16:11834820-11835639:-	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.5982e-06	0.2146
ENSG00000171490.11,RSL1D1	HNSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	2.6127e-06	0.2146
chr16:11834820-11835639:-	KIRC	GSVA_HALLMARK_TGF_BETA_SIGNALING	EER	1.3647e-05	-0.2220
ENSG00000171490.11,RSL1D1	KIRC	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	6.0837e-06	-0.2303
ENSG00000171490.11,RSL1D1	KIRP	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	2.2736e-05	-0.2561
chr16:11834820-11835639:-	KIRP	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	2.4493e-05	-0.2551
ENSG00000171490.11,RSL1D1	LGG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.0865e-15	0.3393
chr16:11834820-11835639:-	LGG	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	9.4714e-17	0.3510
chr16:11834820-11835639:-	LIHC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.3924e-04	-0.2058
ENSG00000171490.11,RSL1D1	LIHC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.0403e-04	-0.2095
chr16:11834820-11835639:-	LUAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	3.8595e-05	0.1841
ENSG00000171490.11,RSL1D1	LUAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	6.1286e-05	0.1793
chr16:11834820-11835639:-	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	2.1965e-03	0.1403
ENSG00000171490.11,RSL1D1	LUSC	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.1288e-03	0.1354
chr16:11834820-11835639:-	MESO	GSVA_HALLMARK_HYPOXIA	EER	1.2515e-04	0.4134
ENSG00000171490.11,RSL1D1	MESO	GSVA_HALLMARK_HYPOXIA	EAG	1.2015e-04	0.4144
ENSG00000171490.11,RSL1D1	OV	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EAG	1.1840e-03	-0.1918
chr16:11834820-11835639:-	OV	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	7.1375e-04	-0.2004
chr16:11834820-11835639:-	PAAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EER	1.4767e-03	0.2413
ENSG00000171490.11,RSL1D1	PAAD	GSVA_HALLMARK_ESTROGEN_RESPONSE_LATE	EAG	1.4398e-03	0.2418
chr16:11834820-11835639:-	PCPG	GSVA_HALLMARK_HEDGEHOG_SIGNALING	EER	2.7794e-03	-0.2205
ENSG00000171490.11,RSL1D1	PCPG	GSVA_HALLMARK_PROTEIN_SECRETION	EAG	2.8360e-03	-0.2201
chr16:11834820-11835639:-	PRAD	GSVA_HALLMARK_UV_RESPONSE_DN	EER	2.1011e-03	-0.1377
ENSG00000171490.11,RSL1D1	PRAD	GSVA_HALLMARK_HEME_METABOLISM	EAG	9.6651e-05	-0.1738
ENSG00000171490.11,RSL1D1	SARC	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.3016e-02	-0.1575
chr16:11834820-11835639:-	SARC	GSVA_HALLMARK_UV_RESPONSE_DN	EER	1.5356e-02	-0.1538
chr16:11834820-11835639:-	SKCM	GSVA_HALLMARK_UV_RESPONSE_DN	EER	2.3663e-04	-0.1740
ENSG00000171490.11,RSL1D1	SKCM	GSVA_HALLMARK_UV_RESPONSE_DN	EAG	1.5279e-04	-0.1792
chr16:11834820-11835639:-	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EER	1.2284e-04	0.2118
ENSG00000171490.11,RSL1D1	STAD	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	7.9012e-04	0.1850
ENSG00000171490.11,RSL1D1	TGCT	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	3.9760e-02	0.1857
ENSG00000171490.11,RSL1D1	THCA	GSVA_HALLMARK_HEME_METABOLISM	EAG	1.3257e-07	-0.2328
chr16:11834820-11835639:-	THCA	GSVA_HALLMARK_HEME_METABOLISM	EER	6.0057e-07	-0.2206
ENSG00000171490.11,RSL1D1	THYM	GSVA_HALLMARK_MITOTIC_SPINDLE	EAG	2.0891e-06	-0.4311
chr16:11834820-11835639:-	THYM	GSVA_HALLMARK_MITOTIC_SPINDLE	EER	2.0949e-06	-0.4310
chr16:11834820-11835639:-	UCEC	GSVA_HALLMARK_NOTCH_SIGNALING	EER	4.7588e-04	-0.2714
ENSG00000171490.11,RSL1D1	UCEC	GSVA_HALLMARK_NOTCH_SIGNALING	EAG	4.5178e-04	-0.2725
ENSG00000171490.11,RSL1D1	UCS	GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE	EAG	1.7407e-02	0.3195
chr16:11834820-11835639:-	UVM	GSVA_HALLMARK_ANDROGEN_RESPONSE	EER	2.0377e-06	-0.5140
ENSG00000171490.11,RSL1D1	UVM	GSVA_HALLMARK_ANDROGEN_RESPONSE	EAG	1.9319e-06	-0.5150

Top

7. Enriched editing regions and drugs for RSL1D1

Correlations between enriched editing regions and drug sensitivity.

* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.

* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).

* EER: enriched editing region, EAG: EER-associated genes.

* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.

ID_events	cancer	Drug	Type	P	R	CorrelationPlot
chr16:11834820-11835639:-	ACC	AZD6244	EER	4.2597e-02	0.2364
ENSG00000171490.11,RSL1D1	ACC	AZD6244	EAG	4.4004e-02	0.2348
ENSG00000171490.11,RSL1D1	BLCA	EHT.1864	EAG	2.5619e-05	0.2181
chr16:11834820-11835639:-	BLCA	EHT.1864	EER	2.2326e-05	0.2197
ENSG00000171490.11,RSL1D1	BRCA	A.770041	EAG	9.0374e-05	-0.1192
chr16:11834820-11835639:-	BRCA	Bryostatin.1	EER	5.1129e-04	-0.1059
chr16:11834820-11835639:-	CESC	CGP.60474	EER	1.7717e-04	-0.2219
ENSG00000171490.11,RSL1D1	CESC	CGP.60474	EAG	1.7264e-04	-0.2222
ENSG00000171490.11,RSL1D1	CHOL	MG.132	EAG	4.0905e-02	-0.3474
chr16:11834820-11835639:-	COAD	AMG.706	EER	2.5444e-02	0.1388
ENSG00000171490.11,RSL1D1	COAD	AMG.706	EAG	2.1813e-02	0.1417
chr16:11834820-11835639:-	DLBC	Etoposide	EER	1.7578e-04	0.5309
ENSG00000171490.11,RSL1D1	DLBC	Etoposide	EAG	1.7578e-04	0.5309
ENSG00000171490.11,RSL1D1	ESCA	Axitinib	EAG	3.3045e-04	0.2838
chr16:11834820-11835639:-	ESCA	Axitinib	EER	4.9568e-04	0.2765
ENSG00000171490.11,RSL1D1	GBM	Metformin	EAG	3.6866e-07	-0.3813
chr16:11834820-11835639:-	GBM	Metformin	EER	4.3851e-07	-0.3790
chr16:11834820-11835639:-	HNSC	Erlotinib	EER	3.8091e-08	-0.2500
ENSG00000171490.11,RSL1D1	HNSC	Docetaxel	EAG	2.7200e-08	-0.2526
ENSG00000171490.11,RSL1D1	KICH	Bleomycin	EAG	1.6068e-02	0.3149
chr16:11834820-11835639:-	KICH	Bleomycin	EER	1.6068e-02	0.3149
chr16:11834820-11835639:-	KIRC	Embelin	EER	9.9412e-12	0.3412
ENSG00000171490.11,RSL1D1	KIRC	Embelin	EAG	2.8602e-11	0.3335
ENSG00000171490.11,RSL1D1	KIRP	AZD6244	EAG	1.4904e-04	-0.2301
chr16:11834820-11835639:-	KIRP	AZD6244	EER	1.5149e-04	-0.2298
chr16:11834820-11835639:-	LGG	Metformin	EER	3.6990e-24	-0.4215
ENSG00000171490.11,RSL1D1	LGG	Metformin	EAG	6.4029e-25	-0.4279
chr16:11834820-11835639:-	LIHC	GW843682X	EER	2.5051e-05	0.2271
ENSG00000171490.11,RSL1D1	LIHC	GW843682X	EAG	2.0823e-05	0.2292
chr16:11834820-11835639:-	LUAD	CMK	EER	1.0638e-02	-0.1148
ENSG00000171490.11,RSL1D1	LUAD	CMK	EAG	1.3637e-02	-0.1109
chr16:11834820-11835639:-	LUSC	CMK	EER	1.1729e-04	-0.1760
ENSG00000171490.11,RSL1D1	LUSC	CMK	EAG	1.0846e-04	-0.1769
chr16:11834820-11835639:-	MESO	BIRB.0796	EER	2.9677e-06	0.4928
ENSG00000171490.11,RSL1D1	MESO	BIRB.0796	EAG	2.7271e-06	0.4943
ENSG00000171490.11,RSL1D1	OV	Embelin	EAG	2.3131e-04	0.2172
chr16:11834820-11835639:-	OV	CCT007093	EER	3.4919e-04	0.2115
ENSG00000171490.11,RSL1D1	PAAD	BIBW2992	EAG	5.8323e-06	-0.3388
chr16:11834820-11835639:-	PAAD	BIBW2992	EER	5.9534e-06	-0.3385
ENSG00000171490.11,RSL1D1	PCPG	BMS.536924	EAG	2.9896e-03	-0.2195
chr16:11834820-11835639:-	PCPG	BMS.536924	EER	2.5029e-03	-0.2234
ENSG00000171490.11,RSL1D1	PRAD	Camptothecin	EAG	5.9327e-06	-0.2014
chr16:11834820-11835639:-	PRAD	Camptothecin	EER	7.0643e-07	-0.2203
ENSG00000171490.11,RSL1D1	READ	Lapatinib	EAG	9.8685e-03	0.2649
chr16:11834820-11835639:-	READ	Lapatinib	EER	1.0536e-02	0.2627
chr16:11834820-11835639:-	SARC	FH535	EER	2.3824e-03	0.1921
ENSG00000171490.11,RSL1D1	SARC	FH535	EAG	2.4759e-03	0.1914
chr16:11834820-11835639:-	SKCM	AZD6244	EER	7.2028e-06	-0.2116
ENSG00000171490.11,RSL1D1	SKCM	AZD6244	EAG	6.3073e-06	-0.2129
ENSG00000171490.11,RSL1D1	STAD	AG.014699	EAG	3.5326e-03	0.1611
chr16:11834820-11835639:-	STAD	BAY.61.3606	EER	3.8699e-03	0.1601
ENSG00000171490.11,RSL1D1	TGCT	Gefitinib	EAG	9.5709e-03	-0.2328
ENSG00000171490.11,RSL1D1	THCA	Embelin	EAG	2.6421e-13	0.3186
chr16:11834820-11835639:-	THCA	Embelin	EER	1.0308e-12	0.3109
ENSG00000171490.11,RSL1D1	THYM	Embelin	EAG	1.1638e-07	0.4756
chr16:11834820-11835639:-	THYM	Embelin	EER	1.1965e-07	0.4752
ENSG00000171490.11,RSL1D1	UCEC	Axitinib	EAG	6.9085e-04	0.2639
chr16:11834820-11835639:-	UCEC	Axitinib	EER	7.0324e-04	0.2635
ENSG00000171490.11,RSL1D1	UCS	Cisplatin	EAG	5.6063e-05	-0.5156
chr16:11834820-11835639:-	UVM	GSK269962A	EER	7.1240e-05	-0.4395
ENSG00000171490.11,RSL1D1	UVM	GSK269962A	EAG	6.0828e-05	-0.4432

Top

EAGs targeted by drugs from DrugBank database.

* EAG: EER-associated genes.

EER

ENST

UniprotID

DrugBankID

Drug

DrugType